Oncology

EXPERIMENTAL THERAPEUTIC TARGET ADMINISTRATION DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 INDICATION
Diakine™- DK210 (EGFR)
wild type IL-2, high affinity IL-10		 EGFR Subcutaneous

Skin, Kidney, Lung, Bladder,

Pancreatic, Colorectal, Head & Neck
Diakine™- DK1210 (EGFR)
IL-12, high affinity IL-10		 EGFR Subcutaneous
Diakine™- DK1510 (EGFR)
IL-15, high affinity IL-10		 EGFR Subcutaneous
Diakine™- DK710 (EGFR)
IL-7, high affinity IL-10		 EGFR Subcutaneous
Diakine™- DKIFN-α 10 (EGFR)
IFN-α, high affinity IL-10		 EGFR Subcutaneous
Diakine™- DK210 (VEGFR2)
wild type IL-2, high affinity IL-10		 VEGFR2 Subcutaneous

All Solid Cancers
Diakine™- DK127 (EGFR)
aglycosylated IL-12, IL-7		 EGFR Intratumoral Injection

Various Solid Cancers
Diakine™- DK12IFN-α (EGFR)
aglycosylated IL-12, IFN-α		 EGFR Intratumoral Injection
Diakine™- DK210 (CD19)
wild type IL-2, high affinity IL-10		 CD19 Subcutaneous

Hematological Cancers
Diakine™- DK210 (CD20)
wild type IL-2, high affinity IL-10		 CD20 Subcutaneous

Inflammatory Disease

AGENT TARGET ADMINISTRATION DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 INDICATION
Diakine™- DK410 (MAdCAM)
IL-4, low affinity IL-10		 MAdCAM Subcutaneous

Inflammatory Bowel Disease
Diakine™- DK410 (VEGFR2)
IL-4, low affinity IL-10		 VEGFR2 Subcutaneous

Psoriasis/Rheumatoid Arthritis
Diakine™- DK410 (CD14)
IL-4, low affinity IL-10		 CD14 Subcutaneous

Sepsis

ONCOLOGY
Diakine™- DK210 (EGFR)
wild type IL-2, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DK1210 (EGFR)
IL-12, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DK1510 (EGFR)
IL-15, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DK710 (EGFR)
IL-7, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DKalpha10 (EGFR)
IFN-α, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DK210 (VEGFR2)
wild type IL-2, high affinity IL-10
TARGET: VEGFR2
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

All Solid Cancers
Diakine™- DK127 (EGFR)
aglycosylated IL-12, IL-7
TARGET: EGFR
ADMINISTRATION: Intratumoral Injection
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Various Solid Cancers
Diakine™- DK12alpha (EGFR)
aglycosylated IL-12, IFN-α
TARGET: EGFR
ADMINISTRATION: Intratumoral Injection
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Various Solid Cancers
Diakine™- DK210 (CD19)
wild type IL-2, high affinity IL-10
TARGET: CD19
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Hematological Cancers
Diakine™- DK210 (CD20)
wild type IL-2, high affinity IL-10
TARGET: CD20
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Hematological Cancers


INFLAMMATORY DISEASE
Diakine™- DK410 (MAdCAM)
IL-4, low affinity IL-10
TARGET: MAdCAM
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Inflammatory Bowel Disease
Diakine™- DK410 (VEGFR2)
IL-4, low affinity IL-10
TARGET: VEGFR2
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Psoriasis/Rheumatoid Arthritis
Diakine™- DK410 (CD14)
IL-4, low affinity IL-10
TARGET: CD14
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Sepsis

Oncology

EXPERIMENTAL THERAPEUTIC TARGET ADMINISTRATION DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 INDICATION
Diakine™- DK210 (EGFR)
wild type IL-2, high affinity IL-10		 EGFR Subcutaneous

Skin, Kidney, Lung, Bladder,

Pancreatic, Colorectal, Head & Neck
Diakine™- DK1210 (EGFR)
IL-12, high affinity IL-10		 EGFR Subcutaneous
Diakine™- DK1510 (EGFR)
IL-15, high affinity IL-10		 EGFR Subcutaneous
Diakine™- DK710 (EGFR)
IL-7, high affinity IL-10		 EGFR Subcutaneous
Diakine™- DKIFN-α 10 (EGFR)
IFN-α, high affinity IL-10		 EGFR Subcutaneous
Diakine™- DK210 (VEGFR2)
wild type IL-2, high affinity IL-10		 VEGFR2 Subcutaneous

All Solid Cancers
Diakine™- DK127 (EGFR)
aglycosylated IL-12, IL-7		 EGFR Intratumoral Injection

Various Solid Cancers
Diakine™- DK12IFN-α (EGFR)
aglycosylated IL-12, IFN-α		 EGFR Intratumoral Injection
Diakine™- DK210 (CD19)
wild type IL-2, high affinity IL-10		 CD19 Subcutaneous

Hematological Cancers
Diakine™- DK210 (CD20)
wild type IL-2, high affinity IL-10		 CD20 Subcutaneous

Inflammatory Disease

AGENT TARGET ADMINISTRATION DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1 INDICATION
Diakine™- DK410 (MAdCAM)
IL-4, low affinity IL-10		 MAdCAM Subcutaneous

Inflammatory Bowel Disease
Diakine™- DK410 (VEGFR2)
IL-4, low affinity IL-10		 VEGFR2 Subcutaneous

Psoriasis/Rheumatoid Arthritis
Diakine™- DK410 (CD14)
IL-4, low affinity IL-10		 CD14 Subcutaneous

Sepsis

ONCOLOGY
Diakine™- DK210 (EGFR)
wild type IL-2, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DK1210 (EGFR)
IL-12, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DK1510 (EGFR)
IL-15, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DK710 (EGFR)
IL-7, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DKalpha10 (EGFR)
IFN-α, high affinity IL-10
TARGET: EGFR
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Skin, Kidney, Lung, Bladder,
Pancreatic, Colorectal, Head & Neck
Diakine™- DK210 (VEGFR2)
wild type IL-2, high affinity IL-10
TARGET: VEGFR2
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

All Solid Cancers
Diakine™- DK127 (EGFR)
aglycosylated IL-12, IL-7
TARGET: EGFR
ADMINISTRATION: Intratumoral Injection
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Various Solid Cancers
Diakine™- DK12alpha (EGFR)
aglycosylated IL-12, IFN-α
TARGET: EGFR
ADMINISTRATION: Intratumoral Injection
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Various Solid Cancers
Diakine™- DK210 (CD19)
wild type IL-2, high affinity IL-10
TARGET: CD19
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Hematological Cancers
Diakine™- DK210 (CD20)
wild type IL-2, high affinity IL-10
TARGET: CD20
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Hematological Cancers


INFLAMMATORY DISEASE
Diakine™- DK410 (MAdCAM)
IL-4, low affinity IL-10
TARGET: MAdCAM
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Inflammatory Bowel Disease
Diakine™- DK410 (VEGFR2)
IL-4, low affinity IL-10
TARGET: VEGFR2
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Psoriasis/Rheumatoid Arthritis
Diakine™- DK410 (CD14)
IL-4, low affinity IL-10
TARGET: CD14
ADMINISTRATION: Subcutaneous
DISCOVERY OPTIMIZATION IN VITRO PROOF IN VIVO PROOF TOXICOLOGY IND READY PHASE 1

Sepsis